Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Outcomes according to Primary Treatment in Gastric Cancer Patients with Peritoneal Seeding

  • Bae, Jung-Min (Department of Surgery, Yeungnam University College of Medicine) ;
  • Yeo, Kyoung-Joon (Department of Surgery, Yeungnam University College of Medicine) ;
  • Kim, Se-Won (Department of Surgery, Yeungnam University College of Medicine) ;
  • Kim, Sang-Woon (Department of Surgery, Yeungnam University College of Medicine) ;
  • Song, Sun-Kyo (Department of Surgery, Yeungnam University College of Medicine)
  • Received : 2011.06.21
  • Accepted : 2011.09.06
  • Published : 2011.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Peritoneal seeding of gastric cancer is known to have a poor prognosis. With the diagnosis of peritoneal seeding, there is no effective treatment modality. Gastrectomy with chemotherapy or primary chemotherapy is basically one of major options for this condition. This study was conducted to compare the clinical outcomes of these treatments and to identify the better way to improve the prognosis of patients with peritoneal seeding. Materials and Methods: Between 2001 and 2007, gastric cancer patients with peritoneal seeding by preoperative or intraoperative diagnosis were reviewed retrospectively. The enrolled patients were divided as primary gastrectomy and primary chemotherapy group. Clinicopathologic characteristics and clinical outcomes of groups were analyzed and compared. Results: Fifty-four patients were enrolled. 21 patients belonged to the group of primary gastrectomy and 33 patients were to the primary chemotherapy group. Among 33 patients of the primary chemotherapy group, 17 patients were received only chemotherapy and 16 patients were received gastrectomy due to the good responses of primary chemotherapy. The 3 years survival rates were 14% in primary gastrectomy group, 55% in patients who received gastrectomy after primary chemotherapy, and 0% in patients with primary chemotherapy only. Conclusions: Although this study had many limitations, some valuable information was produced. In terms of survival benefits for the gastric cancer patients with peritoneal seeding, primary gastrectomy and additional gastrectomy after primary chemotherapy revealed the better clinical outcomes. But, prospective randomized clinical study and multi-center study should be performed to decide proper treatment for gastric cancer patients with peritoneal seeding.

Keywords

References

  1. Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol 1986;7:13- 18. https://doi.org/10.1016/S0167-8140(86)80120-7
  2. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19:1357-1362. https://doi.org/10.1016/0360-3016(90)90344-J
  3. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
  4. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991;15:530-535. https://doi.org/10.1007/BF01675656
  5. Ryu KW, Mok YJ, Kim SJ, Kim CS. Prognostic factors in advanced gastric cancer with peritoneal carcinomatosis. J Korean Surg Soc 2000;59:786-792.
  6. Chu DZ, Lang NP, Th ompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364- 367. https://doi.org/10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V
  7. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-363. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O
  8. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-1326.
  9. D'Ugo D, Persiani R, Rausei S, Biondi A, Vigorita V, Boccia S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol 2006;32:1105-1109. https://doi.org/10.1016/j.ejso.2006.07.009
  10. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96- 107. https://doi.org/10.1159/000012086
  11. Stern JL, Denman S, Elias EG, Didolkar M, Holyoke ED. Evaluation of palliative resection in advanced carcinoma of the stomach. Surgery 1975;77:291-298.
  12. Kim HI, Ha TK, Kwon SJ. Prognostic factors in gastric cancer patients with peritoneal carcinomatosis. J Gastric Cancer 2010;10:126-132. https://doi.org/10.5230/jgc.2010.10.3.126
  13. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998;1:10-24.
  14. Ikeguchi M, Oka A, Tsujitani S, Maeta M, Kaibara N. Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer. Anticancer Res 1994;14:2131-2134.
  15. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003;12:703-727. https://doi.org/10.1016/S1055-3207(03)00048-6
  16. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250:242-246. https://doi.org/10.1097/SLA.0b013e3181b0c80e
  17. Hunerbein M, Rau B, Hohenberger P, Schlag PM. Th e role of staging laparoscopy for multimodal therapy of gastrointestinal cancer. Surg Endosc 1998;12:921-925. https://doi.org/10.1007/s004649900747
  18. Song SC, Lee SL, Cho YK, Han SU. The role and efficacy of diagnostic laparoscopy to detect the peritoneal recurrence of gastric cancer. J Korean Gastric Cancer Assoc 2009;9:51-56.
  19. Shimizu H, Imamura H, Ohta K, Miyazaki Y, Kishimoto T, Fukunaga M, et al. Usefulness of staging laparoscopy for advanced gastric cancer. Surg Today 2010;40:119-124. https://doi.org/10.1007/s00595-009-4017-6
  20. Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 2006;32:661-665. https://doi.org/10.1016/j.ejso.2006.03.007
  21. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370-2377. https://doi.org/10.1245/s10434-010-1039-7
  22. Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA, Lupo PJ, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol 2008;15:2684-2691. https://doi.org/10.1245/s10434-008-0055-3
  23. Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T. Predictive factors improving survival aft er gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010;34:555-562. https://doi.org/10.1007/s00268-010-0396-5
  24. Kwon SJ. Investigation of long-term survivors with stage IV gastric cancer. J Korean Gastric Cancer Assoc 2002;2:157-162. https://doi.org/10.5230/jkgca.2002.2.3.157
  25. Seo YJ, Bae JM, Kim SW, Kim SW, Song SK. Diff erent clinical outcomes of stage IV gastric cancer according to the curability of surgery. J Korean Surg Soc 2009;77:170-176. https://doi.org/10.4174/jkss.2009.77.3.170
  26. Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for therapy? Semin Surg Oncol 1989;5:414-419. https://doi.org/10.1002/ssu.2980050607
  27. Yoon SY, Kim MG, Oh ST. Th e impact of preoperative chemotherapy on the surgical management of unresectable gastric cancer. J Korean Gastric Cancer Assoc 2009;9:269-274.

Cited by

  1. RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells vol.19, pp.1, 2011, https://doi.org/10.1007/s10120-014-0454-z
  2. A novel intraperitoneal therapy for gastric cancer with DFP‐10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model vol.8, pp.17, 2011, https://doi.org/10.1002/cam4.2598